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Background. Knowledge about real-world use of duloxetine and venlafaxine XR to treat depression in the UK is limited. Aims.
To identify predictors of duloxetine or venlafaxine XR initiation. Method. Adult depressed patients who initiated duloxetine or
venlafaxine XR between January 1, 2006 and September 30, 2007 were identiﬁed in the UK’s General Practice Research Database.
Demographic and clinical predictors of treatment initiation with duloxetine and venlafaxine XR were identiﬁed using logistic
regression.Results. Patientsinitiatingduloxetine(n = 909)were4yearsolderthanvenlafaxineXRrecipients(n = 1286).Olderage,
preexisting unexplained pain, respiratory disease, and pre-period use of anticonvulsants, opioids, and antihyperlipidemics were
associated with increased odds of initiating duloxetine compared to venlafaxine XR. Pre-period anxiety disorder was associated
with decreased odds of receiving duloxetine. Conclusion. Initial treatment choice with duloxetine versus venlafaxine XR was
primarily driven by patient-speciﬁc mental and medical health characteristics. General practitioners in the UK favor duloxetine
over venlafaxine XR when pain conditions coexist with depression.
1.Introduction
Major depressive disorder (MDD) is a mood disorder char-
acterized by persistent feelings of sadness, a pervasive
low mood, diminished ability to experience pleasure, and
c o g n i t i v es y m p t o m ss u c ha sd i ﬃculty concentrating and
impaired memory. In addition to the array of emotional and
cognitive symptoms of depression, people with depression
often have physical symptoms that do not respond well
to treatment, such as frequent headaches, digestive prob-
lems, and chronic pain. Taken together, the symptoms of
depression can lead to signiﬁcant impairments in cognitive,
physical, and social functioning. In the UK, the prevalence
of depression is 2.6% among those aged 16–74, with a
slightly higher rate among females [1]. A total of 1.24
million people were estimated having depression in England
in 2007 [2]. A variety of pharmacologic treatments are
available to alleviate the symptoms of depression, includ-
ing tricyclic antidepressants (TCAs), monoamine oxidase
inhibitors (MAOIs), selective serotonin reuptake inhibitors
(SSRIs), and dopamine reuptake inhibitors. Serotonin nore-
pinephrinereuptakeinhibitors(SNRIs),arelativelynewclass
of antidepressant medications, have a selective enhancing
eﬀect on both serotonin and norepinephrine neurotrans-
mission. Introduced in 1995 in the UK, venlafaxine XR is
a SNRI indicated for major depressive disorder, generalized
anxiety disorder, social anxiety disorder, and panic disorder.
Duloxetine, marketed in 2005, is approved for treatment of
major depressive disorder, diabetic peripheral neuropathic
pain, and generalized anxiety disorder.
In recent years, studies have evaluated the eﬃcacy of
SNRIs compared to SSRIs as well as the use of SNRIs in
patients with severe depression [3–6]. Eﬃcacy and cost eﬀec-
tiveness among duloxetine and venlafaxine XR have also2 Depression Research and Treatment
been compared [7–10]. Using the Global Beneﬁt-Risk (GBR)
assessment, Perahia et al. [10] reported similar overall risk-
beneﬁt proﬁles for duloxetine and venlafaxine XR from
two randomized controlled studies of patients receiving
either duloxetine 60mg/day or venlafaxine XR 150mg/day.
Although no signiﬁcant diﬀerences in the major eﬃcacy
measures were observed, a higher percentage of patients
in the venlafaxine arm completed 12 weeks of treatment.
Duloxetine-treatedpatientsweremorelikelytoreportnausea
as a treatment-emergent adverse event than venlafaxine-
treated patients, and venlafaxine-treated patients were more
likely to suﬀer from discontinuation-emergent adverse
events during the taper period than were duloxetine-treated
patients. Additionally, venlafaxine-treated patients were
more likely to suﬀer from discontinuation-emergent adverse
events during the taper period than were duloxetine-treated
patients. The venlafaxine arm also had a higher rate of sus-
tained, elevated systolic blood pressure than the duloxetine
armduringtheﬁxeddosingperiod.Currently,bothdrugsare
recommendedassecond-linetreatmentfordepressionbythe
National Institute for Health and Clinical Excellence (NICE)
in the UK [11]. In response to postmarketing reports sug-
gesting potential cardiovascular toxicity of venlafaxine XR,
the Medicines and Healthcare products Regulatory Agency
(MHRA) in the UK issued a warning for patients with heart
disease treated with venlafaxine XR in 2006. Venlafaxine
is contraindicated in patients with high risk of cardiac
ventricular arrhythmia and uncontrolled hypertension [12].
The use of duloxetine monotherapy versus venlafaxine
and other antidepressants among patients with MDD in the
real-world setting has been examined in several retrospective
claim-based studies. Based on the Veterans Health Adminis-
trationintheUnitedStates(US),Shietal.[13]suggestedthat
prior opioid use, moderate-to-severe pain, and substance
abuse were predictors of duloxetine initiation comparing to
nonduloxetineantidepressants.UsingUSadministrativedata
from 2004 to 2006, Ye et al. [14] evaluated the predictors
of treatment with duloxetine and venlafaxine XR. Older
age, previously treated with SSRIs, TCAs, other antidepres-
sants, anticonvulsants, atypical antipsychotics, analgesics,
hypnotics, muscle relaxants, stimulants, or antihistamines,
presence of sleeping disorder, receiving 3 or more diﬀerent
pain medications in the pre-period, being treated by psy-
chiatrists, were found as signiﬁcant predictors of duloxetine
initiation. However, to our best knowledge, there is no
similar study examining the impact of patient characteristics
on treatment choice with duloxetine or venlafaxine XR
in clinical practice outside of the US. To address this
knowledge gap, this study analyzed the demographic and
clinical characteristics of patients with depression in the UK
who initiated pharmacologic treatment with duloxetine or
venlafaxine XR and identiﬁed predictors of treatment choice
using multivariate regression.
2.MaterialsandMethods
2.1. Data Sources. Study patients were identiﬁed from the
General Practice Research Database (GPRD), which contains
detailed, and deidentiﬁed medical information on enrollees
in the UK’s primary care system. The study sample was
extracted in February, 2009, at a time when the GPRD
had over 8.9 million research-useable patients, including
3 million active enrollees from nearly 350 primary care
practices throughout the UK. These represented a 5.5%
subsample generalizable to the entire population of patients
in UK’s primary care health system at the time. The
database provides comprehensive, longitudinal data from
real-world clinical practices including symptoms, diagnoses,
medication orders, procedures, tests, immunizations, and
patient demographic characteristics and is widely used in
health outcomes and epidemiological research. Because our
study did not involve the collection, use, or transmittal
of individually identiﬁable data, Institutional Review Board
(IRB) oversight was not required.
2.2. Patient Selection Criteria. Patients with at least one
prescription order for duloxetine or venlafaxine XR between
January1,2006 andSeptember30, 2007wereidentiﬁedfrom
the GPRD. All eligible patients were required to be 18 years
or older on the date of the index prescription. Patients were
requiredtobe registered withaGeneral Practice(GP)during
theentirestudyperiod.GPsmusthavereachedtheminimum
required standards for recording data within the practice in
ﬁve areas including registration, prescribing, death, female
health, and referrals at the beginning of the study period.
In addition, at least one patient encounter, face-to-face or
non-face-to-face, was required with a GP in the 36 months
before the index prescription. Patients were required to have
no prescriptions for duloxetine or venlafaxine XR in the six
monthspriortotheindexdateandhaveatleastonediagnosis
of depression in the 12 months prior to or following the
index prescription order. Patients meeting the inclusion
criteria were classiﬁed into one of two treatment cohorts
basedontheirindex SNRItreatmentregimen: (1)duloxetine
or (2) venlafaxine XR. Figure 1 displays the impact of each
inclusion criterion on the ﬁnal sample.
The date of the ﬁrst prescription order for duloxetine or
venlafaxine XR between January 1, 2006 and September 30,
2007 was set as the index date. The 36 months preceding
the index date constituted the pre-period (and included the
clean period of six months for the index SNRI). Preexisting
medical conditions as potential predictors of index SNRI
treatment were evaluated during this period. Pre-period use
of medications as potential predictors of the index treatment
was evaluated during the 12 months immediately preceding
the index date. A longer evaluation period was applied to
medical conditions than medication use because diagnoses,
especially those for chronic conditions, may not be entered
in the GP records each time a patient has an encounter
with a practitioner. The longer evaluation period, therefore,
increased the chances of capturing all diagnoses of interest.
2.3. Dependent Variable. T h eo b j e c t i v eo ft h i ss t u d yw a st o
identify predictors of treatment initiation with duloxetine or
venlafaxine XR among patients with depression. The depen-
dent variable was a dichotomous indicator of receiving theDepression Research and Treatment 3
Patients who were 18 + years of age with 1 + prescription for
duloxetine or venlafaxine XR during 1/1/2006–9/30/2007
Patients had a registration data with a GP practice which passed the data
collection criteria at least 36 months prior to the index date
Patients with 1+ encounter recorded in the GPRD consultation
ﬁle during the 36-month pre-period
Patients without any use of the index medication during the
6-month pre-period
Duloxetine (n = 909) venlafaxine XR (n = 1286)
Final eligible patients in
the duloxetine cohort
(n = 909)
Final eligible patients in
the venlafaxine XR cohort
(n = 1286 )
Duloxetine (n = 2851) venlafaxine XR (n = 3389)
Duloxetine (n = 3632) venlafaxine XR (n = 5334)
Duloxetine (n = 2850) venlafaxine XR (n = 3377)
Duloxetine (n = 2607) venlafaxine XR (n = 2393)
Patients with 1 + diagnosis of depression ±12months of index date
Figure 1: Patient Selection.
index treatment of duloxetine versus venlafaxine XR. Patient
demographicandbaselineclinicalcharacteristicswereexam-
ined to determine the factors with signiﬁcant impact on the
odds of initiating duloxetine or venlafaxine XR.
2.4. Covariates. Patient demographic characteristics includ-
ed age at index date and gender. A series of binary ﬂags
was created to denote the presence of the following psy-
chiatric diagnoses appearing in the 36-month pre-period:
anxiety disorders, attention deﬁcit hyperactivity disorder,
schizophrenia, bipolar disorder, and alcohol/drug depen-
dence. Additional binary ﬂags were created to denote the
following physical health diagnoses appearing in the 36-
month pre-period: circulatory, respiratory, or digestive sys-
tem diseases; sleep disorders; diabetes; diabetic peripheral
neuropathy (DPN); ﬁbromyalgia; osteoarthritis; chronic
low-back pain; unexplained pain which included joint, mus-
culoskeletal, muscle, noncardiac chest, abdominal, and other
pain. Medical and psychiatric conditions were identiﬁed
through Read/OXMIS codes recorded in the GPRD Clinical
and Referral ﬁles. A list of search terms for each of the
conditionsofinterestwasidentiﬁed.Textstringsearcheswere
conducted to identify relevant Read/OXMIS codes, which
were reviewed jointly by researchers and clinical coding
specialists.Coderangeswithcloseproximitytotheidentiﬁed
Read/OXMIS were also reviewed to ensure that all relevant
c o d e sw e r ec a p t u r e d .
Prescription orders appearing in the 12-months pre-
period for medications used to treat a variety of mental
health conditions were identiﬁed, including antidepressants
(SNRIs, SSRIs, TCAs, MAOIs, and other antidepressants),
anxiolytics/hypnotics/musclerelaxants,antipsychotics,stim-
ulants, antimanics, and anticonvulsants. Similarly, prescrip-
tion orders for medications used to treat various physical
health conditions during the same period were identiﬁed,
including cardiovascular medications, thyroid hormones,
antidiabeticmedications,gastrointestinalmedications,respi-
ratorymedications,andanalgesics(opioids,nonopioids,and
migraine medications).
In addition to the preexisting medical conditions and
pre-index medication use, indicators for any inpatient and
accident and emergency (AE) event in the 12 months
preceding the index date were created. Inpatient events
were determined by the presence of Read/OXMIS codes
and/or consultation types indicating inpatient admission or
discharges recorded in the GPRD consultation, clinical, and
referral ﬁles. Similarly, AE events were identiﬁed by the
presence of relevant Read/OXMIS codes, consultation type,
or provider specialties indicative of AE services.
2.5. Statistical Analysis
2.5.1. Univariate Analysis. Frequency distributions, means,
and standard deviations were used to describe the demo-
graphic and pre-period clinical characteristics of the study
population. Diﬀerences between treatment cohorts in de-
mographic and clinical characteristics were evaluated using
chi-square tests for categorical variables and t-tests for4 Depression Research and Treatment
continuous variables. Diﬀerences with P < 0.05 were
considered statistically signiﬁcant.
2.5.2. Multivariate Analysis. Multivariate logistic regression
was used to determine signiﬁcant predictors of index SNRI
treatment. Patient demographic characteristics, pre-period
medical conditions, and pharmacological treatment com-
mon among patients with depression, pre-period healthcare
utilization, as listed under the “Covariates” section, were
included in the model. The venlafaxine cohort served as the
reference group. The odds ratio (OR) for patients initiating
treatment with duloxetine was computed as the exponential
of the logistic regression coeﬃcient. P values for allORs were
considered statistically signiﬁcant when P<0.05. Stata MP
11 software was used in the multivariate analysis.
3. Results andDiscussion
3.1. Demographic Characteristics. A total of 2,195 patients
were identiﬁed for the analysis with an average age of 47.2
years. Approximately 41% were prescribed duloxetine at
index, while 59% received venlafaxine XR. Women were
overrepresentedinbothtreatmentcohorts,butnosigniﬁcant
diﬀerence was observed in the gender distribution between
groups (67.7%/duloxetine, 64.5%/venlafaxine XR, P =
0.120). On average, patients treated with duloxetine were
4 years older than patients treated with venlafaxine XR
(49.6 ± 16.5 years versus 45.5 ± 16.1y e a r s ;P<0.001).
Higher mean age in the duloxetine cohort was driven by a
higher percentage of patients in the age 65+ group and fewer
patients in 18–34 and 35–44 age ranges (Table 1).
3.2. Clinical Characteristics. Table 2 presents the prevalence
of general physical health and psychiatric conditions as well
as healthcare utilization in the pre-period among patients in
the two treatment cohorts. Patients treated with duloxetine
at index had higher prevalence of a variety of physical health
conditions in the pre-period compared to patients treated
with venlafaxine XR, including diseases of the respiratory
system (7.3 percentage points higher; P<0.001), diseases
of the circulatory system (6.9 percentage points higher,
P<0.001), diseases of the digestive system (5.5 percentage
points higher, P = 0.007), and diabetes (3.8 percentage
points higher, P<0.001). Additionally, patients treated with
duloxetine had higher prevalence of chronic low-back pain
(1.2 percentage points higher, P = 0.002) and unexplained
pain (11.9 percentage points higher, P<0.001) than patients
treated with venlafaxine XR. With the exception of anxiety
disorders, no signiﬁcant diﬀerences were observed between
the two groups in the prevalence of the mental health
conditions evaluated. Patients treated with duloxetine had
a lower pre-period rate of anxiety disorders compared to
venlafaxine XR recipients (3.6 percentage points lower, P =
0.049).
During the 12-month pre-period, 20.7% of patients
treated with duloxetine and 17.4% of patients treated with
venlafaxine XR had an inpatient event, but the diﬀerence
was not statistically signiﬁcant (P = 0.054). Compared to
Table 1: Demographic characteristics of patients Initiating duloxe-
tine or venlafaxine XR.
Duloxetine Venlafaxine XR
P value
n/mean %/SD n/mean %/SD
Number of patients (n) 909 1,286
Female (n, %) 615 67.7% 829 64.5% 0.120
Age (n,% ) <0.001
18–34 177 19.5% 345 26.8% <0.001
35–44 206 22.7% 333 25.9% 0.083
45–54 194 21.3% 254 19.8% 0.362
55–64 156 17.2% 193 15.0% 0.174
65+ 176 19.4% 161 12.5% <0.001
Age (mean, SD) 49.6 16.5 45.5 16.1 <0.001
patients initiating treatment with venlafaxine XR, patients
treatedwithduloxetinehadahigherrateofAEevents(22.8%
versus 19.1%, P = 0.034).
Table 3 displaystheratesofpre-periodmedicationuseby
patientsintheduloxetineandvenlafaxineXRgroups.During
the 12-month pre-index period, patients in both treatment
groups had similar exposure to antidepressant treatment
but some diﬀerences were observed. Approximately three-
quarters of duloxetine and venlafaxine XR patients were
treated with an SSRI in the 12-month pre-index period,
and about one-quarter was prescribed a TCA or other
antidepressant type. In addition, 11%–13% had no evidence
of antidepressant treatment. Compared to venlafaxine XR
recipients, a higher proportion of patients treated with
duloxetine at index received treatment with a TCA (25.1%
versus 21.2%, P = 0.034) or a nonindex SNRI antidepressant
(2.8% versus 0.8%, P = 0.036) in the pre-period.
Patients treated with duloxetine had a higher rate of
use anticonvulsants than patients treated with venlafaxine
XR (4.3 percentage points higher, P<0.001). No statis-
tically signiﬁcant diﬀerences were observed in the utiliza-
tion of other psychiatric medications, including anxiolyt-
ics/hypnotics/muscle relaxants, antipsychotics, stimulants,
andantimanics.Withregardtoanalgesicuse,patientstreated
with duloxetine at index had a higher rate of receiving
opioids (12.5 percentage points higher, P<0.001) and
nonopioids (13.1 percentage points higher, P<0.001) in
the pre-period than patients treated with venlafaxine XR.
Consistent with the pattern observed for the prevalence
of select medical conditions in the pre-period, the use of
cardiovascular medications (12.2 percentage points higher,
P<0.001), thyroid hormones (2.3 percentage points higher,
P = 0.029), antidiabetic medications (4.2 percentage points
higher, P<0.001), and GI medications (8.6 percentage
points higher, P<0.001) was signiﬁcantly higher among
patients prescribed duloxetine compared to patients pre-
scribed venlafaxine XR at index.
3.3. Multivariate Results: Predictors of Index SNRI Treatment
Type. Signiﬁcant results of the multivariate logistic regres-
sion model evaluating predictors of index SNRI treatmentDepression Research and Treatment 5
Table 2: Pre-period clinical characteristics of patients initiating duloxetine or venlafaxine XR.
Duloxetine Venlafaxine XR
P value
n % n %
Diagnosed pain conditions1
Diabetic peripheral neuropathy 3 0.3% 2 0.2% 0.398
Fibromyalgia 48 5.3% 46 3.6% 0.052
Osteoarthritis 62 6.8% 74 5.8% 0.307
Chronic low-back pain 14 1.5% 4 0.3% 0.002
Unexplained pain 413 45.4% 431 33.5% <0.001
Diagnosed psychiatric conditions1
Anxiety disorders 190 20.9% 315 24.5% 0.049
Attention deﬁcit hyperactivity disorder 0 0.0% 2 0.2% 0.234
Schizophrenia 2 0.2% 6 0.5% 0.345
Bipolar disorder 8 0.9% 10 0.8% 0.793
Alcohol/drug dependence 43 4.7% 69 5.4% 0.505
Other diagnosed conditions1
Diseases of the circulatory system 207 22.8% 204 15.9% <0.001
Diseases of the respiratory system 470 51.7% 571 44.4% <0.001
Diseases of the digestive system 317 34.9% 378 29.4% 0.007
Sleep disorders 95 10.5% 133 10.3% 0.934
Diabetes 60 6.6% 36 2.8% <0.001
Healthcare utilization2
Inpatient admission 188 20.7% 224 17.4% 0.054
Accident and emergency Visits 207 22.8% 245 19.1% 0.034
1Comorbid conditions were evaluated during 36-month pre-index period.
2Healthcare utilization was evaluated during 12-month pre-index period.
are presented in Figure 2. Unexplained pain in the pre-
period was associated with 32% higher odds of receiving
duloxetine (OR = 1.32, 95% CI: 1.08–1.61, P = 0.006).
Respiratorysystemdiseaseinthepre-period(OR=1.22,95%
CI: 1.01–1.48, P = 0.038), pre-period use of anticonvulsants
(OR = 1.43, 95% CI: 1.00–2.04, P = 0.048), opioid
analgesics (OR = 1.38, 95% CI: 1.10–1.72, P = 0.005), and
antihyperlipidemics (OR = 1.55, 95% CI: 1.14–2.11, P =
0.005) was also associated with signiﬁcantly higher odds of
initiating treatment with duloxetine. Finally, the presence of
anxietydisordersinthepre-periodwasassociatedwitha22%
lower odds of receiving treatment with duloxetine compared
to venlafaxine XR at index (OR = 0.78, 95% CI: 0.62–0.97,
P = 0.027). Age also signiﬁcantly predicted treatment choice
as an increase of 1 year in age was associated with 0.8%
increase in the odds of receiving duloxetine (OR = 1.01, 95%
CI: 1.00–1.01, P = 0.020).
3.4. Discussion. In 2009, NICE issued updated treatment
guidelines for depression by reviewing the clinical eﬃcacy,
side-eﬀect proﬁles, tolerability, discontinuation symptoms,
safety in overdose, and cost eﬀectiveness of various types
of antidepressants. SSRIs are recommended as the ﬁrst-line
therapy for depression, and a variety of other antidepressant
classes, including the SNRIs. Duloxetine and venlafaxine
XR are suggested as second-line treatment for patients who
have no or minimal response within 2–4 weeks following
ﬁrst-line treatment initiation [11]. Drawing from real-
world experience in the UK’s primary care health system
among patients who received pharmacological treatment for
depression, our study examined a wide array of pretreatment
characteristics as predictors of duloxetine and venlafaxine
XR treatment. Consistent with the NICE guidelines, the
majority of patients in our study were treated with an SSRI
in the 12 months prior to receiving duloxetine or venlafaxine
XR. Duloxetine recipients were, on average 4 years older,
and had higher prevalence of select clinical conditions
including unexplained pain, diabetes, and diseases of the
respiratory, circulatory, and digestive systems in the pre-
period than patients who received venlafaxine XR. Patients
treated with duloxetine also had higher rates of receiving
medications such as cardiovascular medications, thyroid
hormones, antidiabetic medications, and gastrointestinal
medications, as well as a higher rate of AE in the pre-
periodthanpatientstreatedwithvenlafaxineXR.Incontrast,
patients treated with venlafaxine XR at index had a higher
rate of anxiety disorders than those treated with duloxetine.
In our study, depressed patients with unexplained pain
and/or analgesic opioid use had higher odds of receiving
duloxetine than venlafaxine XR. This ﬁnding was consistent
with the recent published Shi et al. [13] study in the US, in
which opioid use and moderate-to-severe pain were iden-
tiﬁed as predictors of duloxetine monotherapy. Similarly,6 Depression Research and Treatment
Table 3: Pre-period medication use1 among patients initiating duloxetine or venlafaxine XR.
Duloxetine Venlafaxine XR
P value
n % n %
Antidepressant—SNRI 16 1.8% 10 0.8% 0.036
Antidepressant—TCAs 228 25.1% 273 21.2% 0.034
Antidepressant—MAOIs 8 0.9% 4 0.3% 0.075
Antidepressant—SSRI 679 74.7% 985 76.6% 0.307
Antidepressant—Other 170 18.7% 236 18.4% 0.835
Anxiolytics/hypnotics/muscle relaxants2 406 44.7% 530 41.2% 0.107
Antipsychotics 135 14.9% 201 15.6% 0.618
Stimulants 12 1.3% 11 0.9% 0.292
Antimanics 19 2.1% 21 1.6% 0.43
Anticonvulsants 86 9.5% 66 5.1% <0.001
Analgesics—opioids3 329 36.2% 305 23.7% <0.001
Analgesics—non-opioids 427 47.0% 436 33.9% <0.001
Analgesics—migraine medications 57 6.3% 86 6.7% 0.697
Cardiovascular Disease Medications 340 37.4% 324 25.2% <0.001
Antihyperlipidemics 189 20.8% 124 9.6% <0.001
Antihypertensives 230 25.3% 186 14.5% <0.001
Other medications 108 11.9% 120 9.3% 0.054
Thyroid hormones 68 7.5% 67 5.2% 0.029
Antidiabetics 72 7.9% 48 3.7% <0.001
GI medications 381 41.9% 429 33.4% <0.001
Respiratory medications 157 17.3% 195 15.2% 0.185
1Medications were evaluated during 12-month pre-index period.
2Included sedatives, hypnotics, muscle relaxants, and all benzodiazepines, some of which are used to treat conditions other than anxiety or insomnia.
3Included all medications under BNF “Opioid analgesics” except codeine formulations used to treat diarrhea and migraine medications that contain codeine
(e.g., Migraleve).
Ye et al. [14] reported that patients were more likely to
receive duloxetine if they had previously received analgesics
or used ≥3 unique pain medications in the pre-period.
Pain often coexists with depression, and the improvement of
painsymptomsisanimportantconsiderationwhendeciding
among treatments for depression. The incidence rates of
DPN in both the duloxetine and venlafaxine XR study
cohortswereverylow,andtheratesforotherpainconditions
such as ﬁbromyalgia, osteoarthritis, and chronic low-back
pain were less than 7%. But unexplained pain was reported
by 45% of duloxetine and 34% of venlafaxine XR patients
in the pre-period. Venlafaxine XR has no indication for pain
conditions, but duloxetine is indicated for DPN in addition
to MDD in the UK and has documented eﬀectiveness in
managing pain in depression [15–18]. Using data from two
pooled clinical trials of 251 duloxetine users and 261 placebo
users, Fava et al. [15] reported that duloxetine signiﬁcantly
reduced pain severity among MDD patients compared to
placebo, and pain reduction was associated with higher
remission rates of MDD. In another placebocontrolled
clinical trial, Brecht et al. [16] reported higher remission rate
ofMDDandbetterresponseratesinpainamongduloxetine-
treated MDD patients with at least moderate pain. In a study
of MDD patients who had less-than-optimal responses to
SSRI and switched to duloxetine, painful physical symptoms
(PPSs)weresigniﬁcantlyimprovedfollowingtheswitch[17].
Clinical eﬀectiveness of duloxetine in the short and long-
term treatment of PPS was also evident among patients with
generalized anxiety disorders [18]. Consistent with these
studies ﬁndings, our study suggested that general practition-
ers in the UK were more likely to choose duloxetine over
venlafaxine XR when pain was coexistent with depression.
Both duloxetine and venlafaxine XR are to be used with
caution in patients with a history of mania, a diagnosis
of bipolar disorder and/or seizures. Our results suggested
that when depressed patients were on anticonvulsants prior
to initiating treatment with venlafaxine XR or duloxetine,
their odds of receiving venlafaxine XR were 30% lower
than duloxetine. This ﬁnding was also consistent with those
from Ye et al. [14] study. Anticonvulsants can be used
to treat a variety of conditions including seizure, bipolar
disorder, and pain conditions such as ﬁbromyalgia and DPN.
Although we did not capture the underlying conditions for
which anticonvulsants were prescribed, the most frequently
used anticonvulsants were gabapentin, pregabalin, lamotrig-
ine, solium valproate, and carbamazepine. Besides treating
epilepsy, most of these medications are often used in man-
aging pain such as neuropathic pain and ﬁbromyalgia [19–
21].Thismayexplainthehigheroddsofinitiatingduloxetine
among patients with pre-period use of anticonvulsants.Depression Research and Treatment 7
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OR = 0.780, 95% CI: 0.620–0.970, P = 0.027
Figure 2: Logistic regression predicting duloxetine or venlafaxine XR at index. (Venlafaxine XR served as the reference group in the model.
Only predictors with statistical signiﬁcance are displayed.)
Venlafaxine XR has additional approved indications in
the UK including generalized anxiety disorder, social anxiety
disorder, and panic disorder. Duloxetine is now indicated
for generalized anxiety disorder, but the indication was not
approved until August 2008, which was at the close of our
study period. This may explain, in part, our ﬁndings that
patients with anxiety disorders had a higher likelihood of
initiating treatment with venlafaxine XR than duloxetine.
Given that clinical trials show noninferiority in terms of
clinical eﬃcacy and tolerability between duloxetine and
venlafaxine XR in the treatment of patients with generalized
anxiety disorders [22], we may see an increasing use of
duloxetine to treat patients with MDD and generalized
anxiety disorders in the future. Finally, our study found that
patients who were on antihyperlipidemics were more likely
to initiate duloxetine than venlafaxine XR. Similarly, the Shi
etal.[13]study reported pre-index diagnosis of dyslipidemia
as a signiﬁcant predictor of initiating duloxetine comparing
to nonduloxetine antidepressants.
Interpreting the results from this study is subject to
several challenges inherent to conducting outcome research
studies with the GPRD. As in any administrative data
source, we assumed the accuracy of codes entered into the
database by providers. Despite a rigorous review process by
researchers and coding specialists to identify Read/OXMIS
codes for the clinical conditions and healthcare utilization
events of interest, it is possible that some relevant codes were
missed while others may have been included erroneously.
Any such omissions or errors could impact the accuracy of
the results presented, but the impact across cohorts should
be consistent. As mentioned in Section 2, chronic conditions
may not be coded as frequently as they are seen. As a
remedy, we extended the pre-period for the evaluation of
chronic conditions, thereby increasing the likelihood of their
capture. We also identiﬁed relevant medication use, which is
sometimes a better indicator of comorbidity than diagnoses
alone. For example, the rate of diabetes in the duloxetine
cohort was 6.6% during the 36-month pre-period using
Read/OXMIS codes, but 7.9% of patients had a prescription
for an antidiabetic medication in the 12 months before the
index date. While these limitations may have hindered us
from accurately reporting the rates of comorbid conditions,
theimpactonbothtreatmentcohortsisexpectedtobeequal.
Pharmaceutical treatment in this study was evaluated
solely on prescription orders recorded by general practi-
tioners. Patients may not ﬁll the prescriptions or take the
medications as prescribed, a factor that cannot be assessed
in the GPRD. Thus, evaluations of prescription medication
use reﬂect how the medications were prescribed, but not
necessarily how patients actually took the medications.
Prescriptions providedinahospitalorsecondarycaresetting
including non-GP practitioners, as well as over-the-counter
medications were not captured. The GPRD is generalizable
to the UK population receiving primary care. But it does
not include the homeless, the incarcerated, members of the
armed forces, or individuals who obtain care in private
practices. Thus, our study results are not generalizable to the
entire UK population.
4. Conclusions
Based on a total of 2,195 patients who newly initiated dulox-
etine or venlafaxine XR, our study suggested that older age,
preexisting unexplained pain, anxiety disorders, and respira-
tory disease, as well as pre-period use of opioid analgesics,
antihyperlipidemics, and anticonvulsants were signiﬁcant
predictors of the initiation of duloxetine versus venlafaxine
XR. In the UK primary care system, treatment choice of
duloxetineorvenlafaxineXRappearstobedrivenbypatient-
speciﬁc mental and medical health characteristics with
general practitioners favoring duloxetine over venlafaxine
XR when pain conditions coexist with depression.
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